BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Chronic urticaria clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for chronic urticaria: 48 (27 sponsors; 15 newly posted in the last 180 days, 2 stopped in the last 180 days; 8 new-entrant sponsors). Momentum score 30.2, rank 6 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 1, Phase 1 6, Phase 2 17, Phase 3 15, Phase 4 0, N/A 9.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Novartis Pharmaceuticals NVS14P3 6, NA 7, P2 131
Celldex Therapeutics CLDX4P3 400
Hangzhou Highlightll Pharmaceutical Co., Ltd3P3 1, P2 220
Jemincare2P3 1, P2 100
Longbio Pharma2P3 1, P1 110
Shanghai Mabgeek Biotech.Co.Ltd2P3 1, P2 111
Beijing InnoCare Pharma Tech Co., Ltd.1P3 100
Akeso new entrant1P2 110
AlphaMol Science Ltd. (Shanghai) new entrant1P1 111
ARS Pharmaceuticals, Inc. SPRY1P2 100
Atridia Pty Ltd. new entrant1EARLY_P1 110
Bambusa Therapeutics BBTX new entrant1P2 110
BeOne Medicines ONC1P1 101
Blueprint Medicines Corporation1P2 101
Calixis Inc. new entrant1P2 110
Celltrion HealthCare France1NA 100
Chengdu Suncadia Medicine Co., Ltd. new entrant1P2 111
Cogent Biosciences, Inc. COGT1P2 100
Enanta Pharmaceuticals, Inc ENTA1P1 100
Granular Therapeutics Limited1P1 100
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. new entrant1P1 110
Jiangsu Hansoh Pharmaceutical Co., Ltd.1P2 100
Keymed Biosciences Co.Ltd1P2 100
Novelty Nobility, Inc. new entrant1P2 111
Pfizer PFE1P2 101

New-entrant sponsors: Akeso, AlphaMol Science Ltd. (Shanghai), Atridia Pty Ltd., Bambusa Therapeutics, Calixis Inc., Chengdu Suncadia Medicine Co., Ltd., Hubei Bio-Pharmaceutical Industrial Technological Institute Inc., Novelty Nobility, Inc..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Chengdu Suncadia Medicine Co., Ltd.NCT07613866 A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous UrticariaChronic Spontaneous Urticarianot yet recruiting190
2026-12-25 est.P2Pfizer PFENCT07219615 A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.Chronic Spontaneous Urticariarecruiting200
2026-12-31 est.P2Blueprint Medicines CorporationNCT06931405 Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)Chronic Inducible Urticaria; Chronic Spontaneous Urticariaactive not recruiting105

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-03 est.P3Novartis Pharmaceuticals NVSNCT05677451 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response Chronic Spontaneous Urticariaactive not recruiting100
2026-11-02 est.P2Keymed Biosciences Co.LtdNCT07166211 Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)Chronic Spontaneous Urticaria (CSU)recruiting48
2026-09-27 est.P1/P2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06864507 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Chronic Spontaneous Urticarianot yet recruiting150
2026-08-12P3Celldex Therapeutics CLDXNCT06445023 A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaChronic Spontaneous Urticariaactive not recruiting963
2026-08-04P3Celldex Therapeutics CLDXNCT06455202 A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Chronic Spontaneous Urticariaactive not recruiting976
2026-07-21P2Jasper Therapeutics, Inc. JSPRNCT06736262 A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic UrticariaUrticaria Chronicterminated67
2026-07-15 est.P2JemincareNCT06509334 Trial of JYB1904 in Chronic Spontaneous Urticaria.Chronic Spontaneous Urticariarecruiting135
2026-07-08P1/P2Jasper Therapeutics, Inc. JSPRNCT06162728 Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous UrtChronic Spontaneous Urticariacompleted87
2026-05-29P2Evommune, Inc. EVMNNCT06873516 Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)Chronic Spontaneous Urticariacompleted182

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "chronic urticaria"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.